IPH.PA - Innate Pharma SA Stock Price & Dividend Safety Sector: Healthcare | Exchange: Euronext Paris Current Price & Safety Score Price: 1.28 EUR StockBonds Safety Grade: F Altman Z-Score (Bankruptcy Risk): -22.90 StockBond Score: -1.70 Company Description Innate Pharma SA is a biotechnology firm dedicated to the discovery development and commercialization of innovative antibodybased therapies primarily for cancer indications operating both in France and internationally The companys pipeline includes several key drug candidates Lacutamab IPH4102 an antiKIR3DL2 antibody is currently in Phase II clinical trials for treating cutaneous Tcell and peripheral Tcell lymphoma as well as refractory Sezary syndrome Monalizumab an immune checkpoint inhibitor is undergoing Phase III evaluation for advanced solid tumors encompassing colorectal lung and head and neck cancers Avdoralimab IPH5401 a monoclonal antibody designed to block C5a binding to C5aR1 is advancing through Phase II studies for conditions such as COVID19 bullous pemphigoid chronic spontaneous urticaria and other inflammatory diseases IPH5201 a blocking antibody is in Phase I clinical trials aiming to modulate the CD39 immunosuppressive pathway IPH5301 an antiCD73 antibody targets the immunosuppressive adenosine pathway to foster antitumor immunity IPH6101 an NKp46based NK cell engager is being developed for the creation and assessment of up to two bispecific NK cell engagers Beyond clinical stages their preclinical programs feature IPH43 an antiMICAB antibody drug conjugate an AntiSiglec9 antibody program IPH65 a proprietary tetraspecific antibody IPH25 a checkpoint inhibitor along with the IPH62 and IPH64 programs Innate Pharma SA maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca Novo Nordisk AS Sanofi and Orega Biotech in addition to a codevelopment and licensing agreement with MedImmune Limited The company was founded in 1999 and has its headquarters located in Marseille France